[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Relapsing-remitting multiple sclerosis - Pipeline Insight, 2021

June 2021 | 60 pages | ID: RF9BCF213E0FEN
DelveInsight

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 48 Hours

DelveInsight’s, “Relapsing-remitting multiple sclerosis - Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Relapsing-remitting multiple sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Relapsing-remitting multiple sclerosis Understanding

Relapsing-remitting multiple sclerosis: Overview

Relapsing-remitting multiple sclerosis (RRMS) - the most common disease course – is characterized by clearly defined attacks of new or increasing neurologic symptoms. These attacks – also called relapses or exacerbations – are followed by periods of partial or complete recovery (remissions). During remissions, all symptoms may disappear, or some symptoms may continue and become permanent. However, there is no apparent progression of the disease during the periods of remission.RRMS can be further characterized as either active (with relapses and/or evidence of new MRI activity over a specified period of time) or not active, as well as worsening (a confirmed increase in disability following a relapse) or not worsening. Approximately 85 percent of people with MS are initially diagnosed with RRMS.

'Relapsing-remitting multiple sclerosis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Relapsing-remitting multiple sclerosis pipeline landscape is provided which includes the disease overview and Relapsing-remitting multiple sclerosis treatment guidelines. The assessment part of the report embraces, in depth Relapsing-remitting multiple sclerosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Relapsing-remitting multiple sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Relapsing-remitting multiple sclerosis R&D. The therapies under development are focused on novel approaches to treat/improve Relapsing-remitting multiple sclerosis.
Relapsing-remitting multiple sclerosis Emerging Drugs Chapters

This segment of the Relapsing-remitting multiple sclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Relapsing-remitting multiple sclerosis Emerging Drugs
  • Orelabrutinib: InnoCare Pharma
Orelabrutinib is an orally bioavailable small molecule Bruton's tyrosine kinase-inhibitor (agammaglobulinaemia tyrosine kinase inhibitor), developed by InnoCare Pharma. The drug is in phase 2 stage of development for the treatment of Relapsing Remitting Multiple Sclerosis.
  • BCD-063: Biocad
Biocad is developing glatiramer acetate, designated BCD 063, for the treatment of Relapsing-remitting Multiple Sclerosis. It is a MHC class II gene modulators and is currently in phase 3 stage of development.
  • Evobrutinib: Merck
Evobrutinib (M2951) is in clinical development to investigate its potential as a treatment for multiple sclerosis (MS). It is an oral, highly selective inhibitor of Bruton’s tyrosine kinase (BTK) which is important in the development and functioning of various immune cells including B lymphocytes and macrophages. Evobrutinib is designed to inhibit primary B cell responses such as proliferation and antibody and cytokine release, without directly affecting T cells. BTK inhibition is thought to suppress autoantibody-producing cells, which preclinical research suggests may be therapeutically useful in certain autoimmune diseases. Evobrutinib is currently under clinical investigation and not approved for any use anywhere in the world.

Further product details are provided in the report..

Relapsing-remitting multiple sclerosis: Therapeutic Assessment

This segment of the report provides insights about the different Relapsing-remitting multiple sclerosis drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Relapsing-remitting multiple sclerosis
There are approx. 25+ key companies which are developing the therapies for Relapsing-remitting multiple sclerosis. The companies which have their Relapsing-remitting multiple sclerosis drug candidates in the most advanced stage, i.e. phase III include, Biocad.
  • Phases
DelveInsight’s report covers around 25+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Relapsing-remitting multiple sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Relapsing-remitting multiple sclerosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Relapsing-remitting multiple sclerosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Relapsing-remitting multiple sclerosis drugs.

Relapsing-remitting multiple sclerosis Report Insights
  • Relapsing-remitting multiple sclerosis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Relapsing-remitting multiple sclerosis Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Relapsing-remitting multiple sclerosis drugs?
  • How many Relapsing-remitting multiple sclerosis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Relapsing-remitting multiple sclerosis?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Relapsing-remitting multiple sclerosis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Relapsing-remitting multiple sclerosis and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • InnoCare Pharma
  • Biocad
  • Biogen
  • RedHill Biopharma Limited
  • Immunic AG
  • Merck Serono
  • Anokion SA
  • Apitope Technology
  • Neurotec Pharma
  • Mitsubishi Tanabe Pharma Corporation
  • TG Therapeutics, Inc.
  • RemeGen Co., Ltd.
  • Gilead Sciences
  • GlaxoSmithKline
  • GeNeuro SA
  • InteKrin Therapeutics, Inc.
  • Clene Nanomedicine
  • Takeda Pharmaceuticals
  • Mapi Pharma Ltd.
Key Products
  • Orelabrutinib
  • BCD-063
  • BIIB-019
  • RHB-104
  • IMU-838
  • Evobrutinib
  • ANK-700
  • ATX-MS-1467
  • NT-KO-003
  • MT-1303
  • TMP001
  • Ublituximab
  • RC18
  • BCD-132
  • TENOFOVIR ALAFENAMIDE
  • Belimumab
  • GNbAC1
  • INT131
  • CNM-Au8
  • Ixazomib
  • GA Depot
Introduction
Executive Summary
Relapsing-remitting multiple sclerosis: Overview
  Causes
  Mechanism of Action
  Signs and Symptoms
  Diagnosis
  Disease Management
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
Relapsing-remitting multiple sclerosis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
  Relapsing-remitting multiple sclerosis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Relapsing-remitting multiple sclerosis Collaboration Deals
  Company-Company Collaborations (Licensing / Partnering) Analysis
  Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  Comparative Analysis
Evobrutinib: Merck
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
  Comparative Analysis
RHB-104: RedHill Biopharma Limited
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report..
Inactive Products
  Comparative Analysis
Relapsing-remitting multiple sclerosis Key Companies
Relapsing-remitting multiple sclerosis Key Products
Relapsing-remitting multiple sclerosis- Unmet Needs
Relapsing-remitting multiple sclerosis- Market Drivers and Barriers
Relapsing-remitting multiple sclerosis- Future Perspectives and Conclusion
Relapsing-remitting multiple sclerosis Analyst Views
Relapsing-remitting multiple sclerosis Key Companies
Appendix

LIST OF TABLES

Table 1 Total Products for Relapsing-remitting multiple sclerosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products


LIST OF FIGURES

Figure 1 Total Products for Relapsing-remitting multiple sclerosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products


More Publications